跳至主要内容
临床试验/NCT06227195
NCT06227195已完成不适用

Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis

Shufeng Li1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Number of Breg

研究概览

简要总结

Our previous work has shown that Treg function is impaired in OA patients, but the cause of Treg deficiency has not been investigated. Since Breg has been shown to promote Treg differentiation and tissue repair, it is highly likely that the absence of the immunomodulatory effect of Breg in OA patients leads to impaired Treg differentiation. Based on the above data, we hypothesized that Breg plays a protective role in the course of OA by regulating T cell composition and promoting Treg differentiation through the secretion of anti-inflammatory factor IL-10

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who met the American College of Rheumatology diagnostic criteria for OA

排除标准

  • Patients with trauma, other forms of arthritis such as rheumatoid arthritis, psoriatic arthritis or spondyloarthritis, and other active inflammatory diseases

结局指标

主要结局

Number of Breg

时间窗: 4 and 8 weeks after DMM

Regulatory B cells

次要结局

  • Cytokine secretion by T cells(4 and 8 weeks after DMM)

研究者

发起方
Shufeng Li
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Shufeng Li

Chief Physician

Qianfoshan Hospital

研究点 (1)

Loading locations...

相似试验

Mechanism of IL-10 Pathway-mediated Regulatory B... | 临床试验